Key result
An activated protein C variant lacking specific N-linked glycans (APC-L38D/N329Q) demonstrated 5-fold enhanced endothelial barrier protection and 30-fold improved anti-apoptotic function versus wild type.
Why the study?
Does modification of N-linked glycans on Activated Protein C improve cytoprotective signaling in endothelial cells?
Does modification of N-linked glycans on Activated Protein C improve cytoprotective signaling in endothelial cells?
Effect estimate: 5-fold enhanced barrier protection and 30-fold improved anti-apoptotic function
N-linked glycosylation of Activated Protein C, particularly at Asn-329, plays a critical role in modulating its endothelial cytoprotective and anti-apoptotic functions.
Glycan-modified APC may enhance endothelial cytoprotection; leaves open translation from animal models to human disease.
Activated protein C (APC) has potent anticoagulant and anti-inflammatory properties that limit clot formation, inhibit apoptosis, and protect vascular endothelial cell barrier integrity. In this study, the role of N-linked glycans in modulating APC endothelial cytoprotective signaling via endothelial cell protein C receptor/protease-activated receptor 1 (PAR1) was investigated. Enzymatic digestion of APC N-linked glycans (PNG-APC) decreased the APC concentration required to achieve half-maximal inhibition of thrombin-induced endothelial cell barrier permeability by 6-fold. Furthermore, PNG-APC exhibited increased protection against staurosporine-induced endothelial cell apoptosis when compared with untreated APC. To investigate the specific N-linked glycans responsible, recombinant APC variants were generated in which each N-linked glycan attachment site was eliminated. Of these, APC-N329Q was up to 5-fold more efficient in protecting endothelial barrier function when compared with wild type APC. Based on these findings, an APC variant (APC-L38D/N329Q) was generated with minimal anticoagulant activity, but 5-fold enhanced endothelial barrier protective function and 30-fold improved anti-apoptotic function when compared with wild type APC. These data highlight the previously unidentified role of APC N-linked glycosylation in modulating endothelial cell protein C receptor-dependent cytoprotective signaling via PAR1. Furthermore, our data suggest that plasma β-protein C, characterized by aberrant N-linked glycosylation at Asn-329, may be particularly important for maintenance of APC cytoprotective functions in vivo.
No takes yet. Share an insight, caveat, or question.
Áinle et al. (2010) studied Endothelial cell barrier permeability and apoptosis. Recombinant APC variants lacking specific N-linked glycans (e.g., APC-L38D/N329Q) vs. Wild type APC was evaluated on Endothelial cell barrier protective function and anti-apoptotic function (5-fold enhanced barrier protection and 30-fold improved anti-apoptotic function). An activated protein C variant lacking specific N-linked glycans (APC-L38D/N329Q) demonstrated 5-fold enhanced endothelial barrier protection and 30-fold improved anti-apoptotic function versus wild type.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: